Loading…
China's best-known hemorrhoid-ointment brand, now also selling musk-based skincare and other OTC health products.
China's best-known hemorrhoid-ointment brand, now also selling musk-based skincare and other OTC health products.
Depends on one product family: the musk hemorrhoid ointment and suppositories, sold mostly through pharmacy chains and online, dominate what the company earns. Skincare and other OTC health products, many using the same musk ingredient, are its route to broaden that base.
In one line: A single-brand Chinese Preparation H maker.
Moat: narrow (brand). Decades-old, near-household-name OTC brand with strong pharmacy shelf presence.
Headquarters: Wuhan, China · Employees: 2,544
Size Mayinglong Pharmaceutical (600993.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.62B, the 1528th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥25.05 on 6 Nov 2026.
Performance Over six months the shares fell 3.8%, against -4.2% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 6.6% over the last twelve months (peer median +3.0%); the operating margin is 16.7% (peer median 10.4%).
Valuation It trades at 16.2× forward earnings against a peer median of 27.8× (3rd cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 15.9 points above its cost of capital (5.5% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.99B | CN¥3.84B | CN¥3.70B | CN¥3.11B | CN¥3.51B |
| Revenue growth | — | +4% | +19% | -11% | — |
| Gross profit | CN¥1.90B | CN¥1.83B | CN¥1.67B | CN¥1.25B | CN¥1.43B |
| EBITDA | n/a | CN¥745M | CN¥675M | CN¥471M | CN¥577M |
| Net income | CN¥595M | CN¥581M | CN¥528M | CN¥443M | CN¥479M |
| Free cash flow | CN¥691M | CN¥481M | CN¥294M | CN¥373M | CN¥297M |
| Capital expenditure | CN¥106M | CN¥119M | CN¥204M | CN¥248M | CN¥75.0M |
| Total debt | CN¥246M | CN¥252M | CN¥398M | CN¥380M | CN¥801M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Mayinglong Pharmaceutical 600993.SS | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600993.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.6% | +2.3% | 6th highest of 21 |
| 6-month return | -3.8% | -4.2% | 10th highest of 20 |
| Distance from 52-week high | -17.0% | -19.8% | 7th highest of 21 |
| Revenue growth (TTM) | +6.6% | +3.0% | 9th highest of 19 |
| Operating margin | 16.7% | 10.4% | 5th highest of 19 |
| Forward P/E | 16.2× | 27.8× | 3rd cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -4.5% | 11.0% | 4th least demanding of 13 |
| Growth delivered (Del g) | +6.8% | +11.7% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | -11.2 pp | -2.1 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | +15.9 pp | +1.3 pp | 3rd highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |